Display options
Cite
Ng JC, Leung M, Landsberg D. Evaluation of Heparin Anticoagulation Protocols in Post-Renal Transplant Recipients (EHAP-PoRT Study). Can J Hosp Pharm. 2016;69(2):114-21doi: 10.4212/cjhp.v69i2.1538.
Ng, J. C., Leung, M., & Landsberg, D. (2016). Evaluation of Heparin Anticoagulation Protocols in Post-Renal Transplant Recipients (EHAP-PoRT Study). The Canadian journal of hospital pharmacy, 69(2), 114-21. https://doi.org/10.4212/cjhp.v69i2.1538
Ng, Joan Chung Yan, et al. "Evaluation of Heparin Anticoagulation Protocols in Post-Renal Transplant Recipients (EHAP-PoRT Study)." The Canadian journal of hospital pharmacy vol. 69,2 (2016): 114-21. doi: https://doi.org/10.4212/cjhp.v69i2.1538
Ng JC, Leung M, Landsberg D. Evaluation of Heparin Anticoagulation Protocols in Post-Renal Transplant Recipients (EHAP-PoRT Study). Can J Hosp Pharm. 2016 Mar-Apr;69(2):114-21. doi: 10.4212/cjhp.v69i2.1538. Epub 2016 Apr 29. PMID: 27168632; PMCID: PMC4853178.
Copy Download .nbib Format: NLM
Share it on

Can J Hosp Pharm. 2016 Mar-Apr;69(2):114-21. doi: 10.4212/cjhp.v69i2.1538. Epub 2016 Apr 29.

Evaluation of Heparin Anticoagulation Protocols in Post-Renal Transplant Recipients (EHAP-PoRT Study).

The Canadian journal of hospital pharmacy

Joan Chung Yan Ng, Marianna Leung, David Landsberg

Affiliations

  1. BSc(Pharm), ACPR, was, at the time of this study, a Pharmacy Resident with Lower Mainland Pharmacy Services in Vancouver, British Columbia. She is now a Clinical Pharmacist with Providence Health Care and a student in the graduate Doctor of Pharmacy program at the University of British Columbia, Vancouver, British Columbia.
  2. BSc(Pharm), ACPR, PharmD, is a Clinical Pharmacy Specialist, Transplant, with Providence Health Care, and a Clinical Assistant Professor with the University of British Columbia, Vancouver, British Columbia.
  3. MD, FRCPC, is Renal Program Director with Providence Health Care, Medical Director of Kidney Transplantation with the BC Transplant Society, and Clinical Professor with the University of British Columbia, Vancouver, British Columbia.

PMID: 27168632 PMCID: PMC4853178 DOI: 10.4212/cjhp.v69i2.1538

Abstract

BACKGROUND: Disturbances in hemostasis are common among renal transplant recipients. Because of the risk of thromboembolism and graft loss after transplant, a prophylactic heparin protocol was implemented at St Paul's Hospital in Vancouver, British Columbia, in 2011. Therapeutic heparin is sometimes prescribed perioperatively for patients with preexisting prothrombotic conditions. There is currently limited literature on the safety and efficacy of heparin use in the early postoperative period.

OBJECTIVES: The primary objectives were to document, for patients who underwent renal transplant, the incidence of major bleeding and of thrombosis in those receiving therapeutic heparin, prophylactic heparin, and no heparin anticoagulation in the early postoperative period and to compare these rates for the latter 2 groups. The secondary objectives included a comparison of the risk factors associated with major bleeding and thrombosis.

METHODS: Adult patients who received a renal transplant at St Paul's Hospital between January 2008 and July 2013 were included in this retrospective cohort study. Electronic health records and databases were used to divide patients into the 3 heparin-use cohorts, to identify cases of major bleeding and thrombosis, and to characterize patients and events. The Fisher exact test was used for the primary outcome analysis, and descriptive statistics were used for all other outcomes.

RESULTS: A total of 547 patients were included in the analysis. Major bleeding was observed in 6 (46%) of the 13 patients who received therapeutic heparin; no cases of thrombosis occurred in these patients. Major bleeding occurred in 8 (3.0%) of the 266 patients who received prophylactic heparin and 9 (3.4%) of the 268 who received no heparin (p > 0.99). Thrombosis occurred in 1 (0.4%) and 3 (1.1%) of these patients, respectively (p = 0.62). Major bleeding occurred more frequently among patients with a low-target heparin protocol, but 61% of values for partial thromboplastin time were above target. A larger proportion of deceased-donor transplant recipients who had major bleeding were taking antiplatelet agents, relative to living-donor transplant recipients.

CONCLUSION: Therapeutic use of heparin increased the risk of bleeding among renal transplant recipients, but there were no cases of thrombosis. Prophylactic use of heparin did not increase the risk of bleeding and prevented proportionately more cases of thrombosis relative to no anticoagulation; this result supports the continued use of prophylaxis.

Keywords: hemorrhage; heparin; kidney transplantation; postoperative anticoagulation; thrombosis

References

  1. Transplant Proc. 2005 Mar;37(2):1026-8 - PubMed
  2. Semin Thromb Hemost. 2010 Feb;36(1):34-40 - PubMed
  3. Transplantation. 2005 Sep 27;80(6):789-93 - PubMed
  4. Ann Pharmacother. 2004 Apr;38(4):537-43 - PubMed
  5. Blood Rev. 2011 Nov;25(6):271-8 - PubMed
  6. Ann Clin Lab Sci. 2003 Fall;33(4):396-400 - PubMed
  7. N Engl J Med. 1994 Aug 11;331(6):365-76 - PubMed
  8. Hosp Pharm. 2013 Dec;48(11):936-57 - PubMed
  9. Transplantation. 1989 Nov;48(5):886-7 - PubMed
  10. Chest. 2012 Feb;141(2 Suppl):e326S-50S - PubMed
  11. Am J Transplant. 2007 Jul;7(7):1865-8 - PubMed
  12. Nephrol Dial Transplant. 1996 Jan;11(1):140-7 - PubMed
  13. Transplant Proc. 2012 Jul-Aug;44(6):1690-3 - PubMed
  14. Urology. 2007 Apr;69(4):647-51 - PubMed

Publication Types